# Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

> **NCT06589219** · PHASE1 · RECRUITING · sponsor: **Calibr, a division of Scripps Research** · enrollment: 106 (estimated)

## Conditions studied

- Pulmonary Fibroses, Idiopathic

## Interventions

- **DRUG:** CMR316
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06589219
- **Lead sponsor:** Calibr, a division of Scripps Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589219, "Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06589219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*